Eye Disease News and Research

RSS

Eye diseases are widespread around the globe. According to the World Health Organization, the most important three eye diseases or conditions that are a potential threat to the global population are diabetic retinopathy, glaucoma, and age-related macular degeneration. One more vital reason for visual harm is refractive errors. Some of the important reasons for vision loss or low vision are age, healthcare, gender, genetic problems and the prevalence of family history.

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

Marking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior Minister of State for Trade and Industry and Education, S. Iswaran, at the Biopolis on Nov. 3, 2009.

4 Nov 2009

ThromboGenics issues business update for the third-quarter of 2009

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, is today issuing a business update for the period ending 30 September, 2009.

4 Nov 2009

Multicenter study finds AMD patients can benefit from cataract surgery

This month's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy) reports on a national study that finds cataract surgery is likely to benefit patients with age-related macular degeneration (AMD) at all stages of the disease, on a clinical trial showing that the steroid triamcinolone may be effective in advanced diabetic macular edema (DME) patients when standard treatment fails, and on the public's use of two Academy-sponsored online eye health forums.

2 Nov 2009

Combination of inhibitor and antioxidants may help prevent diabetes complications

In diabetes patients, high blood glucose levels can end up killing certain cells in the eyes and kidneys, which is why diabetes is the leading cause of adult blindness and of kidney failure. Years ago, scientists identified one main route for this destruction—high glucose produces oxidative stress through the NF-kB molecular pathway—but success has been elusive for drugs targeting that pathway.

2 Nov 2009

Annual dilated eye exam helps prevent vision loss in people with diabetes

Diabetes causes more new cases of legal blindness among working-age Americans than any other disease. If diabetics are monitored regularly by their ophthalmologist, this vision loss is almost always avoidable. Yet, tragically, more than half of all people living with diabetes do not get the recommended annual dilated eye exam.

30 Oct 2009

Veterans with TBI vision loss have poor quality of life compared to civilian patients

Pan-American Association of Ophthalmology (PAAO) Joint Meeting, includes a Veterans Administration study that indicates that Iraq and Afghanistan veterans with vision loss from traumatic brain injury have significantly poorer quality of life than comparable civilian patients, and a Harvard doctor's insights on how to best evaluate and care for low-vision patients who experience vivid visual hallucinations due to Charles Bonnet syndrome.

28 Oct 2009

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

Isotechnika Pharma Inc. today announced that results of the international Phase 2/3 clinical trials studying voclosporin, conducted by its partner Lux Biosciences, were the subject of two podium presentations at the American Association of Ophthalmology (AAO) meeting and of a presentation at the satellite meeting of the American Uveitis Society (AUS) in San Francisco, October 24-27.

27 Oct 2009

CWRU grants licensing agreement to Bioptigen for FDOCT technology

Case Western Reserve University and University Hospitals Case Medical Center have granted to Bioptigen, of Research Triangle Park, N.C ., an exclusive intellectual property licensing agreement for Fourier domain optical coherence tomography (FDOCT), an imaging technology developed from research at the university's Department of Biomedical Engineering.

27 Oct 2009

LX211 may become the first approved oral treatment for modifying the course of uveitis

An experimental drug, LX211 (LUVENIQ - oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use.

27 Oct 2009

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

The ARVO Foundation for Eye Research (AFER) and Pfizer Ophthalmics are pleased to announce a series of awards named in honor of Carl B. Camras, MD. Up to three awards of $10,000 each will be presented annually for a period of 10 years to early career researchers.

24 Oct 2009

OIS EyeScan and OIS Symphony Digital Reporter systems to feature at AAO Annual Meeting

Ophthalmic Imaging Systems ("OIS" or "the Company") (OTCBB: OISI), a leading digital imaging and informatics company, today announced that it will launch two new products and improvements to the OIS EMR and OIS PM solutions at the American Academy of Ophthalmology's (AAO) 113th Annual Meeting, being held October 24 - 27, 2009, at the Moscone Convention Center in San Francisco, CA.

23 Oct 2009

Auxano point-of-care indicator system for dry eye syndrome

Auxano Diagnostics, LLC, a subsidiary of Auxano Biomedical, LLC, has announced the application of the company’s breakthrough wound care technology to the treatment of dry eye syndrome (DES) with the Auxano point-of-care indicator system.

21 Oct 2009

Retinal prosthesis restores partial vision to people who are totally blind

Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Researchers also reported that an engineered protein restored vision in an animal model and identified ways to improve stem cell treatments.

21 Oct 2009

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Several cell-based therapy approaches could provide new treatments for patients with Alport syndrome, reports an upcoming paper in the Journal of the American Society of Nephrology (JASN). "Our study opens up many considerations of how new therapies related to the use of stem cells can be devised for our kidney patients with chronic disease," comments Raghu Kalluri, MD, PhD (Harvard Medical School, Boston, MA).

19 Oct 2009

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

pSivida Corp., a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today announced that the last patient in the Phase III clinical trial being conducted by its collaborative partner, Alimera Sciences, for a new treatment for diabetic macular edema (DME) has completed the two-year follow up visit.

15 Oct 2009

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD).

9 Oct 2009

IP Advocate collaborates with Marion Kauffman Foundation on education and policy initiatives

Sharing a mutual goal of helping researchers turn their discoveries into products that help people and stimulate the economy, IP Advocate (http://www.IPAdvocate.org) founder and noted scientist Dr. Renee Kaswan is collaborating with the Ewing Marion Kauffman Foundation (http://www.kauffman.org) on a range of education and policy initiatives.

7 Oct 2009

Researchers identify novel circulation within human eye that provides new insight into glaucoma

Researchers at the University of Toronto, St. Michael's Hospital and Sunnybrook Health Sciences Centre have discovered a previously unidentified form of circulation within the human eye which may provide important new insights into glaucoma, a leading cause of blindness.

6 Oct 2009

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative medicines for eye disease, vascular disease and cancer, today announces results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME).

6 Oct 2009

Study finds that visual impairment in T1D patients may be decreasing

People diagnosed with type 1 diabetes (T1D) in recent years are less likely to develop diabetes-related vision loss than those diagnosed in earlier years, says a new study funded by the National Eye Institute, a division of the National Institutes of Health. Forecasts of visual impairment prevalence in T1D patients may need to be amended, the researchers suggest, since current predictions assume that the earlier incidence rates will continue.

3 Oct 2009

Eye Disease News and Research

Further Reading

IBN iCare to develop cutting-edge nanomaterials for ocular therapy

ThromboGenics issues business update for the third-quarter of 2009

Multicenter study finds AMD patients can benefit from cataract surgery

Combination of inhibitor and antioxidants may help prevent diabetes complications

Annual dilated eye exam helps prevent vision loss in people with diabetes

Veterans with TBI vision loss have poor quality of life compared to civilian patients

Isotechnika Pharma reports voclosporin Phase 2/3 clinical trial results at the AAO meeting

CWRU grants licensing agreement to Bioptigen for FDOCT technology

LX211 may become the first approved oral treatment for modifying the course of uveitis

AFER and Pfizer Ophthalmics initiate awards recognizing the achievements of Dr. Carl B. Camras

OIS EyeScan and OIS Symphony Digital Reporter systems to feature at AAO Annual Meeting

Auxano point-of-care indicator system for dry eye syndrome

Retinal prosthesis restores partial vision to people who are totally blind

Stem cell treatments could repair the kidney defects associated with Alport syndrome

pSivida achieves milestone in Phase III Iluvien trial, last patient completes two-year follow up visit

Controlled trial comparing Bevacizumab to Ranibizumab finds no difference in efficacy

IP Advocate collaborates with Marion Kauffman Foundation on education and policy initiatives

Researchers identify novel circulation within human eye that provides new insight into glaucoma

ThromboGenics presents Phase IIa microplasmin intravitreal injection trial results at the ASRS conference

Study finds that visual impairment in T1D patients may be decreasing

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News